Drug Repurposing for Neurodegenerative Diseases

📖 Wiki Page

therapeutic1414 wordssynced 2026-04-02

Drug Repurposing for Neurodegenerative Diseases

Introduction

...

Drug Repurposing for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Drug Repurposing for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Known Safety</td>
<td>Extensive clinical use data</td>
</tr>
<tr>
<td class="label">Known PK/PD</td>
<td>Established dosing</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Existing production</td>
</tr>
<tr>
<td class="label">Regulatory</td>
<td>Established pathways</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AMPK activation, [mTOR](/entities/mtor) inhibition</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>[Autophagy](/entities/autophagy), mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[GLP-1 receptor](/entities/glp1-receptor) activation</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Neuroprotection, reduced neuroinflammation</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>HMG-CoA reductase inhibition</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Anti-inflammatory, membrane effects</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypertension</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Calcium homeostasis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Target</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>BCR-ABL, c-KIT</td>
</tr>
<tr>
<td class="label">Bosutinib</td>
<td>BCR-ABL</td>
</tr>
<tr>
<td class="label">Dasatinib</td>
<td>BCR-ABL</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Sirolimus</td>
<td>Transplant rejection</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Cancer, tuberous sclerosis</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Bacterial infections</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Anti-inflammatory, microglial modulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Ibuprofen</td>
<td>Pain/inflammation</td>
</tr>
<tr>
<td class="label">Naproxen</td>
<td>Pain/inflammation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Potential Use</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>AD, PD depression</td>
</tr>
<tr>
<td class="label">Fluoxetine</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Depression</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Sleep regulation, anti-[Aβ](/proteins/amyloid-beta)</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Epilepsy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[HDAC](/entities/hdac-enzymes) inhibition, mood stabilization</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Epilepsy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Synaptic modulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Use</td>
</tr>
<tr>
<td class="label">Amphotericin B</td>
<td>Antifungal</td>
</tr>
<tr>
<td class="label">Atovaquone</td>
<td>Antiprotozoal</td>
</tr>
<tr>
<td class="label">Mebendazole</td>
<td>Anti-parasitic</td>
</tr>
<tr>
<td class="label">Doxycycline</td>
<td>Antibiotic</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Gene Expression</td>
<td>Connective Alchemy 基于表达谱</td>
</tr>
<tr>
<td class="label">Network Analysis</td>
<td>Protein-protein interaction networks</td>
</tr>
<tr>
<td class="label">Signature Matching</td>
<td>Compare disease and drug signatures</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Connectivity Map</td>
<td>Gene expression matching</td>
</tr>
<tr>
<td class="label">Repurpose</td>
<td>Open-source drug database</td>
</tr>
<tr>
<td class="label">DrugBank</td>
<td>Computational screening</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Dapagliflozin</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Atovaquone</td>
<td>Malaria</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>CML</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Metformin + Lifestyle</td>
<td>Metabolic + behavioral</td>
</tr>
<tr>
<td class="label">GLP-1 + Exercise</td>
<td>Synergistic effects</td>
</tr>
<tr>
<td class="label">Senolytic combination</td>
<td>Enhanced clearance</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>HMG-CoA reductase inhibition, anti-inflammatory</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Reduced neuroinflammation, improved cerebral blood flow</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypertension, anxiety</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Beta-adrenergic receptor blockade</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Reduced stress response, neuroprotection</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Chronic myeloid leukemia (dasatinib), CML (nilotinib)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>BCR-ABL inhibition, autophagy induction</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Enhanced [alpha-synuclein](/proteins/alpha-synuclein) clearance, neuroprotection</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Dasatinib + Quercetin</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Autophagy induction via multiple pathways</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Synergistic protein clearance</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Antibacterial (tetracycline)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Microglial activation modulation, anti-inflammatory</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Reduced neuroinflammation</td>
</tr>
</table>

Drug Repurposing For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Drug repurposing (also called drug repositioning) involves identifying new therapeutic uses for existing drugs that were developed for other conditions. This approach offers significant advantages: established safety profiles, known pharmacokinetics, reduced development time, and lower costs [@ashburn2004]. [@campbell2018]

Advantages of Repurposing

Repurposed Drugs in Neurodegeneration

Diabetes Drugs

Metformin

Clinical Evidence:

Reduced dementia risk in diabetics (retrospective)
Ongoing trials in MCI/AD (NCT04098627)
Potential disease-modifying effects [@campbell2018]

GLP-1 Agonists (Exenatide, Liraglutide, Semaglutide)

Clinical Evidence:

Exenatide: Motor improvement in PD (Phase 2)
Liraglutide: Cognitive benefit in AD (Phase 2)
Semaglutide: Trials in AD (Phase 3)
Neuroprotective in preclinical models [@athauda2017]

Cardiovascular Drugs

Statins

Clinical Evidence:

Mixed results in AD prevention
Possible benefit in PD
Ongoing trials for safety signals

Amlodipine

Clinical Evidence:

Reduced AD risk in some studies
Trial in PD (NCT05148806)
[BBB](/entities/blood-brain-barrier)-penetrating statin use studied

Anti-Cancer Drugs

Tyrosine Kinase Inhibitors

Clinical Evidence:

Nilotinib: Phase 2 in PD showed motor improvement
Dasatinib + Quercetin: Senolytic trial in AD
Ongoing trials in PD and AD [@pagan2022]

mTOR Inhibitors

Clinical Evidence:

Sirolimus: Improved cognition in AD mouse models
Everolimus: Trials in TSC-related CNS issues

Anti-Inflammatory Drugs

Minocycline

Clinical Evidence:

Failed in ALS (Phase 3)
No benefit in AD
Preclinical neuroprotection not replicated

NSAIDs

Clinical Evidence:

Observational studies suggested benefit
Prospective trials negative
Timing may be critical

Antidepressants

SSRIs

Clinical Evidence:

Sertraline: Cognitive benefit in depression
Fluoxetine: Motor improvement in PD models

Trazodone

Clinical Evidence:

Sleep benefits in neurodegeneration
Preclinical [Aβ](/proteins/amyloid-beta) reduction
Trial in AD (NCT03042261)

Anti-Epileptic Drugs

Valproic Acid

Clinical Evidence:

Failed in AD
Mood benefits in PD
Liver toxicity concerns

Levetiracetam

Clinical Evidence:

Reduced network hyperexcitability
Cognitive benefits in studies
SV2A modulation

Other Repurposed Agents

High-Throughput Screening Approaches

Bioinformatic Prediction

Drug-Disease Matching

Clinical Trial Landscape

Active Repurposing Trials

Challenges and Limitations

Efficacy Limitations

Modest effect sizes in many cases
Optimal dosing unclear for CNS
Disease-specific considerations

Safety Concerns

Long-term safety in elderly
Drug-drug interactions
Pre-existing conditions

Regulatory Challenges

Patent protection issues
Reformulation needs
Development costs despite advantages

Future Directions

Combination Repurposing

Precision Repurposing

Genetic subtypes informing drug selection
Biomarker-guided approaches
Patient stratification

External Links

[ClinicalTrials.gov - Drug Repurposing](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=repurpos)
[DrugBank](https://go.drugbank.com/)
[Repurpose](https://www.repurpose.io/)

Background

The study of Drug Repurposing For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cardiovascular Drugs

Statins (Atorvastatin, Simvastatin)

Clinical Evidence:

Observational studies show reduced dementia risk with statin use
Ongoing trials in AD (NCT02728856)
Potential for vascular dementia prevention

Beta-Blockers (Propranolol)

Clinical Evidence:

Observational studies link beta-blocker use to reduced AD risk
Phase 2 trial in AD-related agitation (NCT03116156)

Anti-Cancer Drugs

Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib)

Clinical Evidence:

Dasatinib: FDA-approved for CML, trials in PD (Phase 1/2)
Nilotinib: Shows promise in PD/AD trials
Low-dose treatment may reduce toxic protein aggregates

Metformin + Dasatinib Combination

Clinical Evidence:

D+Q (Senolytics): Eliminates senescent cells
Trials in AD, PD, and aging (NCT04685590)

Anti-Inflammatory Drugs

Microglial Modulators (Minocycline)

Clinical Evidence:

Mixed results in ALS and AD trials
Early intervention may be key

References

Ashburn TT, Thor KB, Drug repositioning: identifying and developing new uses for existing drugs (2004)

Campbell JM, et al, Metformin and Alzheimer's disease: a systematic review (2018)

Athauda D, et al, Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2017)

Pagan F, et al, Nilotinib effects in Parkinson's disease and dementia with Lewy bodies (2022)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Drug Repurposing for Neurodegenerative Diseases

Drug Repurposing for Neurodegenerative Diseases

Introduction

Drug Repurposing for Neurodegenerative Diseases

Introduction

Overview

Advantages of Repurposing

Repurposed Drugs in Neurodegeneration

Diabetes Drugs

Metformin

GLP-1 Agonists (Exenatide, Liraglutide, Semaglutide)

Cardiovascular Drugs

Statins

Amlodipine

Anti-Cancer Drugs

Tyrosine Kinase Inhibitors

mTOR Inhibitors

Anti-Inflammatory Drugs

Minocycline

NSAIDs

Antidepressants

SSRIs

Trazodone

Anti-Epileptic Drugs

Valproic Acid

Levetiracetam

Other Repurposed Agents

High-Throughput Screening Approaches

Bioinformatic Prediction

Drug-Disease Matching

Clinical Trial Landscape

Active Repurposing Trials

Challenges and Limitations

Efficacy Limitations

Safety Concerns

Regulatory Challenges

Future Directions

Combination Repurposing

Precision Repurposing

See Also

External Links

Background

Cardiovascular Drugs

Statins (Atorvastatin, Simvastatin)

Beta-Blockers (Propranolol)

Anti-Cancer Drugs

Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib)

Metformin + Dasatinib Combination

Anti-Inflammatory Drugs

Microglial Modulators (Minocycline)

References

Related Hypotheses